BMY vs CTNM: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
BMY is the larger of the two ($122.05B market cap): the incumbent the market prices for continued execution (9.04x forward earnings, beta 0.18). CTNM is the smaller challenger ($266.36M), priced similarly on forward earnings (-3.67x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BMY vs CTNM: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | CTNM | What it tells you |
|---|---|---|---|
| Market cap | $122.05B | $266.36M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 9.04 | -3.67 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.18 | 0.86 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 66% of range | 1% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.47 | 1.11 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BMY and CTNM affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and CTNM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and CTNM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Contineum Therapeutics (CTNM) do?
Contineum Therapeutics, formerly Pipeline Therapeutics, is a San Diego biotech that listed on the Nasdaq in April 2024 through an IPO priced at $16 a share that raised ~$110 million. It develops oral small-molecule drugs for fibrotic, inflammatory and neurological diseases, and it has no approved products. The lead program is PIPE-791, a once-daily oral antagonist of the LPA1 receptor, a lipid-signalling receptor tied to the scarring that drives IPF. PIPE-791 is in PROPEL-IPF, a global, randomized, placebo-controlled Phase 2 trial of ~324 patients whose primary endpoint is the change in forced vital capacity (FVC, how much air a patient can exhale) over 26 weeks. The second asset, PIPE-307, a selective M1 muscarinic receptor inhibitor, is licensed to Johnson & Johnson, which paid $50 million upfront in 2023, bought $25 million of stock, and owes up to ~$1.0 billion in milestones plus royalties if it succeeds. The company makes money today only from interest on its cash.
BMY vs CTNM: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- CTNM drivers: The PROPEL-IPF readout for PIPE-791; What admilparant means for the LPA1 class.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For CTNM, the central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year.
BMY or CTNM: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; CTNM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and CTNM guides.
BMY vs CTNM: the full fundamentals
BMY. At about $60.80 on October 16, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a 40% one-year rally. The 4.2% dividend yield and strong cash flow are the bull-case anchors, while consensus for roughly flat 2027 EPS (about $6.62 versus $6.65 for 2026) captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $66, and Q3 2026 results arrive on October 29.
CTNM. Contineum has no sales and loses money, so price-to-earnings and price-to-sales ratios do not apply. The useful comparison is market value against cash. After the October 12 fall, the enterprise value (market value minus cash) is roughly ~$85 million to ~$100 million, and that is what the market assigns to PIPE-791, the J&J milestones and everything else combined. Price to book is ~1.3, which says the same thing. The next scheduled update is third-quarter results, which should show the cash balance and any word from J&J on PIPE-307.
Headline figures (approximate, October 2026): BMY shows revenue (ttm) ~$49.2 billion (Q2 2026 up ~5.7% YoY), q2 2026 adjusted eps $2.04 vs $1.60 consensus, operating margin ~34%, net income (ttm) ~$9.3 billion; CTNM shows revenue (ttm) ~$0 (no product or collaboration revenue reported in 2026), net loss (q2 2026) ~$15.2 million (vs ~$16.0 million in Q2 2025), r&d expense (q2 2026) ~$12.7 million (down 10% year over year), cash and marketable securities ~$236.6 million (June 30, 2026).
The bottom line: BMY vs CTNM
BMY and CTNM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and CTNM exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or CTNM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Bristol Myers Squibb with AI
Connect the broker you already use and ask Walnut's AI how BMY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BMY and CTNM?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Contineum Therapeutics, formerly Pipeline Therapeutics, is a San Diego biotech that listed on the Nasdaq in April 2024 through an IPO priced at $16 a share that raised ~$110 million. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or CTNM the better stock?
+
Neither is universally better. BMY is the larger incumbent; CTNM is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or CTNM?
+
On forward P/E (as of October 2026), BMY trades at 9.04x and CTNM at -3.67x, so CTNM is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and CTNM?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs CTNM?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in flat to lower revenue and EPS in 2027. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $11 billion of cash, and litigation exposure, add further uncertainty. CTNM: The central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. Even with positive data, admilparant is a Phase 3 asset backed by a large pharma company heading toward filings, so it would likely reach patients years before PIPE-791. The IPF market already includes Boehringer Ingelheim's Ofev (nintedanib), generic pirfenidone and Boehringer's newer nerandomilast, so a late entrant needs clear differentiation on efficacy, tolerability or convenience. PIPE-307 has now missed in two Phase 2 trials (multiple sclerosis in 2025 and depression in 2026), and J&J alone decides whether to continue, so the milestone stream could disappear. The research workforce cut and the departure of the chief scientific officer narrow the pipeline behind PIPE-791. The stock is small and highly sensitive to peer news, as the ~36% one-day fall on a competitor's trial showed, and any Phase 3 would almost certainly need new financing or a partner, which could dilute existing holders.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or CTNM; figures are approximate and dated (as of October 2026). Verify current data before investing.